Rapport Therapeutics, Inc. (RAPP): Submission of Matters to a Vote of Security Holders
Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0002012593 0002012593 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
How this was made
The 30-second read
Why it matters
This is a post-event disclosure of director elections (Class II) and ratification of PwC as independent auditor for FY ending Dec. 31, 2026; it does not disclose new business developments.
Market read
Standard governance recap; not a new catalyst for valuation or risk.
What to watch
Traders may still monitor for follow-on filings (e.g., subsequent 10-K/8-K items) that could carry real fundamental updates, but none are included here.
Background
The company’s SEC 8-K (Item 5.07) summarizes stockholder voting outcomes from its 2026 annual meeting held June 10, 2026.
Ticker impact
Rapport Therapeutics filed an 8-K reporting the results of its June 10, 2026 annual meeting votes, including director elections and PwC ratification.
Low probability of a sustained price move; any reaction is likely limited to event-driven noise.
The filing contains vote tallies for standard items (board slate and auditor ratification) with no new operational, financial, or regulatory developments.
Market effects
Minimal; does not introduce new biotech/therapeutics sector signals.
Minimal; US-listed microcap governance filing.
Minimal; no cross-border transaction or regulatory action described.
Counterpoint
If the vote results were unusually contentious, it could hint at governance friction, but the filing provides no narrative about disputes or outcomes beyond standard tallies.
Key entities
- issuerRapport Therapeutics, Inc.
Nasdaq-listed company filing the 8-K with annual meeting vote results.
- auditorPwC
Ratified as independent registered public accounting firm for fiscal year ending December 31, 2026.
- directorsJames Healy, M.D., Ph.D.; Robert J. Perez; Raymond Sanchez, M.D.
Elected as Class II directors for terms until the 2029 annual meeting (per vote results).
